Virus-Induced Oncogenesis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Shimaa Soliman.

Tumorigenesis due to viral infection accounts for a high fraction of the total global cancer burden (15–20%) of all human cancers. One of the main mechanisms by which viruses induce host cell proliferation programs is through controlling the host’s epigenetic machinery. Oncogenic viruses establish a permanent latent infection sustained by the production of specific viral proteins, which interact with the cell environment, including the host epigenetic machinery to specifically deregulate pathways to their advantage such as cell metabolism, resistance to apoptosis, cell proliferation and innate immune response signaling. Epigenetic modifications largely alter host gene expression and can provide a common mechanism of virus-induced transformation.

  • oncogenic viruses
  • epigenetic
  • HPV
  • HBV
  • HCV
  • MCPyV
  • KSHV
  • HTLV-1
  • EBV
  • HCMV
Please wait, diff process is still running!

References

  1. De Martel, C.; Georges, D.; Bray, F.; Ferlay, J.; Clifford, G.M. Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis. Lancet Glob. Health 2020, 8, e180–e190.
  2. McLaughlin-Drubin, M.E.; Munger, K. Viruses Associated with Human Cancer. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2008, 1782, 127–150.
  3. Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 1911, 13, 397–411.
  4. Weiss, R.A.; Vogt, P.K. 100 Years of Rous Sarcoma Virus. J. Exp. Med. 2011, 208, 2351–2355.
  5. Epstein, M.A.; Barr, Y.M. Cultivation in vitro of human lymphoblasts from burkitt’s malignant lymphoma. Lancet Lond. Engl. 1964, 1, 252–253.
  6. Epstein, M.A.; Barr, Y.M.; Achong, B.G. A second virus-carrying tissue culture strain (eb2) of lymphoblasts from burkitt’s Lymphoma. Pathol. Biol. 1964, 12, 1233–1234.
  7. Henle, W.; Henle, G. Epidemiologic aspects of epstein-barr virus (ebv)-associated diseases. Ann. N. Y. Acad. Sci. 1980, 354, 326–331.
  8. Lever, A.M.; Berkhout, B. 2008 Nobel Prize in Medicine for Discoverers of HIV. Retrovirology 2008, 5, 91.
  9. White, M.K.; Pagano, J.S.; Khalili, K. Viruses and Human Cancers: A Long Road of Discovery of Molecular Paradigms. Clin. Microbiol. Rev. 2014, 27, 463.
  10. Mui, U.N.; Haley, C.T.; Tyring, S.K. Viral Oncology: Molecular Biology and Pathogenesis. J. Clin. Med. 2017, 6, 111.
  11. Mesri, E.A.; Feitelson, M.A.; Munger, K. Human Viral Oncogenesis: A Cancer Hallmarks Analysis. Cell Host Microbe 2014, 15, 266–282.
  12. Krump, N.A.; You, J. Molecular Mechanisms of Viral Oncogenesis in Humans. Nat. Rev. Microbiol. 2018, 16, 684–698.
  13. Read, S.A.; Douglas, M.W. Virus Induced Inflammation and Cancer Development. Inflamm. Gastrointest. Liver Cancers 2014, 345, 174–181.
  14. Zheng, Z.; Sze, C.W.; Keng, C.T.; Al-Haddawi, M.; Liu, M.; Tan, S.Y.; Kwek, H.L.; Her, Z.; Chan, X.Y.; Barnwal, B.; et al. Hepatitis C Virus Mediated Chronic Inflammation and Tumorigenesis in the Humanised Immune System and Liver Mouse Model. PLoS ONE 2017, 12, e0184127.
  15. Fernandes, J.V.; Fernandes, T.; de Medeiros, A.A.; de Azevedo, J.; Veríssimo, C.; Cobucci, R.; Oliveira, N.; de Carvalho, M.; Freire, G.; Andrade, V.; et al. Maria Galvão Link between Chronic Inflammation and Human Papillomavirus-Induced Carcinogenesis (Review). Oncol. Lett. 2015, 9, 1015–1026.
  16. Wyatt, J.; Müller, M.M.; Tavassoli, M. Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death. Cancers 2019, 11, 1975.
  17. Burley, M.; Roberts, S.; Parish, J.L. Epigenetic Regulation of Human Papillomavirus Transcription in the Productive Virus Life Cycle. Semin. Immunopathol. 2020, 42, 159–171.
  18. Durzynska, J.; Lesniewicz, K.; Poreba, E. Human Papillomaviruses in Epigenetic Regulations. Spec. Issue HPV IGF Axis Carcinog. 2017, 772, 36–50.
  19. Zhang, F.; Yuan, Y.; Ma, F. Function and Regulation of Nuclear DNA Sensors During Viral Infection and Tumorigenesis. Front. Immunol. 2021, 11, 3427.
  20. Bird, A. Perceptions of Epigenetics. Nature 2007, 447, 396–398.
  21. Berger, S.L.; Kouzarides, T.; Shiekhattar, R.; Shilatifard, A. An Operational Definition of Epigenetics. Genes Dev. 2009, 23, 781–783.
  22. Tagawa, T.; Serquiña, A.; Kook, I.; Ziegelbauer, J. Viral Non-Coding RNAs: Stealth Strategies in the Tug-of-War between Humans and Herpesviruses. Semin. Cell Dev. Biol. 2021, 111, 135–147.
  23. Tycowski, K.T.; Guo, Y.E.; Lee, N.; Moss, W.N.; Vallery, T.K.; Xie, M.; Steitz, J.A. Viral Noncoding RNAs: More Surprises. Genes Dev. 2015, 29, 567–584.
  24. Feinberg, A.P.; Vogelstein, B. Hypomethylation Distinguishes Genes of Some Human Cancers from Their Normal Counterparts. Nature 1983, 301, 89–92.
  25. Meyer, P. Chapter One—Epigenetics—A Historical Perspective. In Advances in Botanical Research; Mirouze, M., Bucher, E., Gallusci, P., Eds.; Academic Press: New York, NY, USA, 2018; Volume 88, pp. 1–19. ISBN 0065-2296.
  26. Gibney, E.R.; Nolan, C.M. Epigenetics and Gene Expression. Heredity 2010, 105, 4–13.
  27. Tsai, K.; Cullen, B.R. Epigenetic and Epitranscriptomic Regulation of Viral Replication. Nat. Rev. Microbiol. 2020, 18, 559–570.
  28. Rahnamoun, H.; Orozco, P.; Lauberth, S.M. The Role of Enhancer RNAs in Epigenetic Regulation of Gene Expression. Transcription 2020, 11, 19–25.
  29. Chiarella, A.M.; Lu, D.; Hathaway, N.A. Epigenetic Control of a Local Chromatin Landscape. Int. J. Mol. Sci. 2020, 21, 943.
  30. Dandri, M. Epigenetic Modulation in Chronic Hepatitis B Virus Infection. Semin. Immunopathol. 2020, 42, 173–185.
  31. Mac, M.; Moody, C.A. Epigenetic Regulation of the Human Papillomavirus Life Cycle. Pathogens 2020, 9, 483.
  32. Broussard, G.; Damania, B. Regulation of KSHV Latency and Lytic Reactivation. Viruses 2020, 12, 1034.
  33. Domovitz, T.; Gal-Tanamy, M. Tracking down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J. Clin. Med. 2021, 10, 551.
  34. Vojtechova, Z.; Tachezy, R. The Role of MiRNAs in Virus-Mediated Oncogenesis. Int. J. Mol. Sci. 2018, 19, 1217.
  35. Liu, W.; Zhang, Y.; Luo, B. Long Non-Coding RNAs in Gammaherpesvirus Infections: Their Roles in Tumorigenic Mechanisms. Front. Microbiol. 2021, 11, 3420.
  36. Chavez-Calvillo, G.; Martin, S.; Hamm, C.; Sztuba-Solinska, J. The Structure-To-Function Relationships of Gammaherpesvirus-Encoded Long Non-Coding RNAs and Their Contributions to Viral Pathogenesis. Non-Coding RNA 2018, 4, 24.
  37. Rosenberg, E.S.; Rosenthal, E.M.; Hall, E.W.; Barker, L.; Hofmeister, M.G.; Sullivan, P.S.; Dietz, P.; Mermin, J.; Ryerson, A.B. Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw. Open 2018, 1, e186371.
  38. Phillips, M.; Abboud, J.; Abodunde, B.; Paul, D.P.I.; Coustasse, A. The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia. Health Care Manag. 2020, 39, 2–11.
  39. Dhifallah, I.; Khedhiri, M.; Chouikha, A.; Kharroubi, G.; Hammami, W.; Sadraoui, A.; Azzouz, M.M.; Maamouri, N.; Khalfallah, T.; Triki, H.; et al. Hepatitis Viruses Take Advantage of Traditional Practices to Increase the Burden of Hepatocellular Carcinoma in Tunisia. Arch. Virol. 2020, 165, 33–42.
  40. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34.
  41. Pietschmann, T.; Brown, R.J.P. Hepatitis C Virus. Spec. Issue Antimicrob. Resist. Nov. Ther. 2019, 27, 379–380.
  42. Tong, Y.; Lavillette, D.; Li, Q.; Zhong, J. Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. Front. Immunol. 2018, 9, 1411.
  43. Tong, Y.; Chi, X.; Yang, W.; Zhong, J. Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a Trans-Complementation System Reveals a Dual Role of a Putative Fusion Peptide of E1 in Both HCV Entry and Morphogenesis. J. Virol. 2017, 91, e02468-16.
  44. Dubrau, D.; Tortorici, M.A.; Rey, F.A.; Tautz, N. A Positive-Strand RNA Virus Uses Alternative Protein-Protein Interactions within a Viral Protease/Cofactor Complex to Switch between RNA Replication and Virion Morphogenesis. PLoS Pathog. 2017, 13, e1006134.
  45. Chigbu, D.I.; Loonawat, R.; Sehgal, M.; Patel, D.; Jain, P. Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence. Cells 2019, 8, 376.
  46. Haddad, J.G.; Rouillé, Y.; Hanoulle, X.; Descamps, V.; Hamze, M.; Dabboussi, F.; Baumert, T.F.; Duverlie, G.; Lavie, M.; Dubuisson, J. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. J. Virol. 2017, 91, e00048-17.
  47. Sanghera, C.; Teh, J.J.; Pinato, D.J. The Systemic Inflammatory Response as a Source of Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. Liver Int. 2019, 39, 2008–2023.
  48. Chen, H.-J.; Hu, M.-H.; Xu, F.-G.; Xu, H.-J.; She, J.-J.; Xia, H.-P. Understanding the Inflammation-Cancer Transformation in the Development of Primary Liver Cancer. Hepatoma Res. 2018, 4, 29.
  49. Chan, S.L.; Chan, A.W.H.; Chan, A.K.C.; Jian, P.; Mo, F.; Chan, C.M.L.; Mok, K.; Liu, C.; Chong, C.C.N.; Chan, A.T.C.; et al. Systematic Evaluation of Circulating Inflammatory Markers for Hepatocellular Carcinoma. Liver Int. 2017, 37, 280–289.
  50. Lui, F.H.; Moosvi, Z.; Patel, A.; Hussain, S.; Duong, A.; Duong, J.; Nguyen, D.L. Decreased Risk of Hepatocellular Carcinoma Recurrence with Direct-Acting Antivirals Compared with No Treatment for Hepatitis C: A Meta-Analysis. Ann. Gastroenterol. 2020, 33, 293–298.
  51. Buonomo, A.R.; Scotto, R.; Coppola, C.; Pinchera, B.; Viceconte, G.; Rapillo, C.M.; Staiano, L.; Saturnino, M.; Scarano, F.; Portunato, F.; et al. Direct Acting Antivirals Treatment for Hepatitis C Virus Infection Does Not Increase the Incidence of de Novo Hepatocellular Carcinoma Occurrence: Results from an Italian Real-Life Cohort (LINA Cohort). Medicine 2020, 99, e18948.
  52. Lee, H.W.; Han, D.H.; Shin, H.J.; Lee, J.S.; Kim, S.U.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Kim, B.K. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. Cancers 2020, 12, 3414.
  53. Hsu, S.-J.; Yang, S.-S.; Kao, J.-H. Risk of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradicated by Direct-Acting Antivirals: Fact or Fiction? J. Formos. Med. Assoc. Taiwan Yi Zhi 2020, 119, 3–11.
  54. You, M.-W.; Kim, K.W.; Shim, J.-J.; Pyo, J. Impact of Liver-Stiffness Measurement on Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals: A Systematic Review and Time-to-Event Meta-Analysis. J. Gastroenterol. Hepatol. 2020, 36, 601–608.
  55. Wedemeyer, H.; Khera, T.; Strunz, B.; Björkström, N.K. Reversal of Immunity after Clearance of Chronic HCV Infection—All Reset? Front. Immunol. 2020, 11, 2659.
  56. Goto, K.; Roca Suarez, A.A.; Wrensch, F.; Baumert, T.F.; Lupberger, J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int. J. Mol. Sci. 2020, 21, 3057.
  57. Vranjkovic, A.; Deonarine, F.; Kaka, S.; Angel, J.B.; Cooper, C.L.; Crawley, A.M. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. Front. Immunol. 2019, 10, 1926.
  58. Wijaya, R.S.; Read, S.A.; Selvamani, S.P.; Schibeci, S.; Azardaryany, M.K.; Ong, A.; van der Poorten, D.; Lin, R.; Douglas, M.W.; George, J.; et al. Hepatitis C Virus (HCV) Eradication with Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. J. Infect. Dis. 2020.
  59. Hamdane, N.; Jühling, F.; Crouchet, E.; El Saghire, H.; Thumann, C.; Oudot, M.A.; Bandiera, S.; Saviano, A.; Ponsolles, C.; Roca Suarez, A.A.; et al. HCV-Induced Epigenetic Changes Associated with Liver Cancer Risk Persist after Sustained Virologic Response. Gastroenterology 2019, 156, 2313–2329.e7.
  60. Rinaldi, L.; Nevola, R.; Franci, G.; Perrella, A.; Corvino, G.; Marrone, A.; Berretta, M.; Morone, M.V.; Galdiero, M.; Giordano, M.; et al. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers 2020, 12, 1351.
  61. Polyak, S.J.; Crispe, I.N.; Baumert, T.F. Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. Pathogens 2021, 10, 44.
  62. Perez, S.; Gal-Tanamy, M. Studying the Hepatitis C Virus-Induced Epigenetic Signature after Cure with Direct-Acting Antivirals. Methods Mol. Biol. 2019, 1911, 191–207.
  63. Peng, J.; Wu, J.; Li, G.; Wu, J.; Xi, Y.; Li, X.; Wang, L. Association of RASSF1A Hypermethylation with Risk of HBV/HCV-Induced Hepatocellular Carcinoma: A Meta-Analysis. Pathol. Res. Pract. 2020, 216, 153099.
  64. Wijetunga, N.A.; Pascual, M.; Tozour, J.; Delahaye, F.; Alani, M.; Adeyeye, M.; Wolkoff, A.W.; Verma, A.; Greally, J.M. A Pre-Neoplastic Epigenetic Field Defect in HCV-Infected Liver at Transcription Factor Binding Sites and Polycomb Targets. Oncogene 2017, 36, 2030–2044.
  65. Kasai, H.; Mochizuki, K.; Tanaka, T.; Yamashita, A.; Matsuura, Y.; Moriishi, K. Induction of HOX Genes by HCV Infection via Impairment of Histone H2A Monoubiquitination. J. Virol. 2020.
  66. Poiesz, B.J.; Ruscetti, F.W.; Gazdar, A.F.; Bunn, P.A.; Minna, J.D.; Gallo, R.C. Detection and Isolation of Type C Retrovirus Particles from Fresh and Cultured Lymphocytes of a Patient with Cutaneous T-Cell Lymphoma. Proc. Natl. Acad. Sci. USA 1980, 77, 7415.
  67. Matsuoka, M.; Jeang, K.-T. Human T-Cell Leukemia Virus Type 1 (HTLV-1) and Leukemic Transformation: Viral Infectivity, Tax, HBZ and Therapy. Oncogene 2011, 30, 1379–1389.
  68. Ishitsuka, K.; Tamura, K. Human T-Cell Leukaemia Virus Type I and Adult T-Cell Leukaemia-Lymphoma. Lancet Oncol. 2014, 15, e517–e526.
  69. Matsuoka, M.; Yasunaga, J. Human T-Cell Leukemia Virus Type 1: Replication, Proliferation and Propagation by Tax and HTLV-1 BZIP Factor. Virus Replication Anim. Plants 2013, 3, 684–691.
  70. Mesnard, J.-M.; Barbeau, B.; Césaire, R.; Péloponèse, J.-M. Roles of HTLV-1 Basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related Diseases. Viruses 2015, 7, 6490–6505.
  71. Gaudray, G.; Gachon, F.; Basbous, J.; Biard-Piechaczyk, M.; Devaux, C.; Mesnard, J.-M. The Complementary Strand of the Human T-Cell Leukemia Virus Type 1 RNA Genome Encodes a BZIP Transcription Factor That Down-Regulates Viral Transcription. J. Virol. 2002, 76, 12813.
  72. Cheng, H.; Ren, T.; Sun, S. New Insight into the Oncogenic Mechanism of the Retroviral Oncoprotein Tax. Protein Cell 2012, 3, 581–589.
  73. Xiao, G.; Cvijic, M.E.; Fong, A.; Harhaj, E.W.; Uhlik, M.T.; Waterfield, M.; Sun, S.-C. Retroviral Oncoprotein Tax Induces Processing of NF-ΚB2/P100 in T Cells: Evidence for the Involvement of IKKα. EMBO J. 2001, 20, 6805–6815.
  74. Ameur, L.B.; Marie, P.; Thenoz, M.; Giraud, G.; Combe, E.; Claude, J.-B.; Lemaire, S.; Fontrodona, N.; Polveche, H.; Bastien, M.; et al. Intragenic Recruitment of NF-ΚB Drives Splicing Modifications upon Activation by the Oncogene Tax of HTLV-1. Nat. Commun. 2020, 11, 3045.
  75. Abou-Kandil, A.; Eisa, N.; Jabareen, A.; Huleihel, M. Differential Effects of HTLV-1 Tax Oncoprotein on the Different Estrogen-Induced-ER α-Mediated Transcriptional Activities. Cell Cycle Georget. Tex 2016, 15, 2626–2635.
  76. Di, L.-J.; Fernandez, A.G.; De Siervi, A.; Longo, D.L.; Gardner, K. Transcriptional Regulation of BRCA1 Expression by a Metabolic Switch. Nat. Struct. Mol. Biol. 2010, 17, 1406–1413.
  77. Shukrun, M.; Jabareen, A.; Abou-Kandil, A.; Chamias, R.; Aboud, M.; Huleihel, M. HTLV-1 Tax Oncoprotein Inhibits the Estrogen-Induced-ER α-Mediated BRCA1 Expression by Interaction with CBP/P300 Cofactors. PLoS ONE 2014, 9, e89390.
  78. Hirata, M.; Shinden, Y.; Nagata, A.; Nomoto, Y.; Saho, H.; Nakajo, A.; Arigami, T.; Kurahara, H.; Maemura, K.; Natsugoe, S.; et al. Clinical Features of Breast Cancer Patients with Human T-Cell Lymphotropic Virus Type-1 Infection. Asian Pac. J. Cancer Prev. 2019, 20, 1909–1912.
  79. Jeong, S.; Liang, G.; Sharma, S.; Lin, J.C.; Choi, S.H.; Han, H.; Yoo, C.B.; Egger, G.; Yang, A.S.; Jones, P.A. Selective Anchoring of DNA Methyltransferases 3A and 3B to Nucleosomes Containing Methylated DNA. Mol. Cell. Biol. 2009, 29, 5366–5376.
  80. Nyborg, J.K.; Egan, D.; Sharma, N. The HTLV-1 Tax Protein: Revealing Mechanisms of Transcriptional Activation through Histone Acetylation and Nucleosome Disassembly. Chromatin Viral Gene Expr. 2010, 1799, 266–274.
  81. Cheng, J.; Kydd, A.R.; Nakase, K.; Noonan, K.M.; Murakami, A.; Tao, H.; Dwyer, M.; Xu, C.; Zhu, Q.; Marasco, W.A. Negative Regulation of the SH2-Homology Containing Protein-Tyrosine Phosphatase-1 (SHP-1) P2 Promoter by the HTLV-1 Tax Oncoprotein. Blood 2007, 110, 2110–2120.
  82. Zhao, T.; Matsuoka, M. HBZ and Its Roles in HTLV-1 Oncogenesis. Front. Microbiol. 2012, 3, 247.
  83. Ma, G.; Yasunaga, J.; Fan, J.; Yanagawa, S.; Matsuoka, M. HTLV-1 BZIP Factor Dysregulates the Wnt Pathways to Support Proliferation and Migration of Adult T-Cell Leukemia Cells. Oncogene 2013, 32, 4222–4230.
  84. Zhao, T.; Satou, Y.; Sugata, K.; Miyazato, P.; Green, P.L.; Imamura, T.; Matsuoka, M. HTLV-1 BZIP Factor Enhances TGF-β Signaling through P300 Coactivator. Blood 2011, 118, 1865–1876.
  85. Zhao, T.; Yasunaga, J.; Satou, Y.; Nakao, M.; Takahashi, M.; Fujii, M.; Matsuoka, M. Human T-Cell Leukemia Virus Type 1 BZIP Factor Selectively Suppresses the Classical Pathway of NF-ΚB. Blood 2009, 113, 2755–2764.
  86. Matsumoto, J.; Ohshima, T.; Isono, O.; Shimotohno, K. HTLV-1 HBZ Suppresses AP-1 Activity by Impairing Both the DNA-Binding Ability and the Stability of c-Jun Protein. Oncogene 2005, 24, 1001–1010.
  87. Satou, Y.; Yasunaga, J.-I.; Zhao, T.; Yoshida, M.; Miyazato, P.; Takai, K.; Shimizu, K.; Ohshima, K.; Green, P.L.; Ohkura, N.; et al. HTLV-1 BZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation in Vivo. PLoS Pathog. 2011, 7, e1001274.
  88. Kuhlmann, A.-S.; Villaudy, J.; Gazzolo, L.; Castellazzi, M.; Mesnard, J.-M.; Duc Dodon, M. HTLV-1 HBZ Cooperates with JunD to Enhance Transcription of the Human Telomerase Reverse Transcriptase Gene (HTERT). Retrovirology 2007, 4, 92.
  89. Zhi, H.; Yang, L.; Kuo, Y.-L.; Ho, Y.-K.; Shih, H.-M.; Giam, C.-Z. NF-ΚB Hyper-Activation by HTLV-1 Tax Induces Cellular Senescence, but Can Be Alleviated by the Viral Anti-Sense Protein HBZ. PLoS Pathog. 2011, 7, e1002025.
  90. Satou, Y.; Miyazato, P.; Ishihara, K.; Yaguchi, H.; Melamed, A.; Miura, M.; Fukuda, A.; Nosaka, K.; Watanabe, T.; Rowan, A.G.; et al. The Retrovirus HTLV-1 Inserts an Ectopic CTCF-Binding Site into the Human Genome. Proc. Natl. Acad. Sci. USA 2016, 113, 3054–3059.
  91. Melamed, A.; Yaguchi, H.; Miura, M.; Witkover, A.; Fitzgerald, T.W.; Birney, E.; Bangham, C.R. The Human Leukemia Virus HTLV-1 Alters the Structure and Transcription of Host Chromatin in Cis. eLife 2018, 7.
  92. Telford, M.; Hughes, D.A.; Juan, D.; Stoneking, M.; Navarro, A.; Santpere, G. Expanding the Geographic Characterisation of Epstein–Barr Virus Variation through Gene-Based Approaches. Microorganisms 2020, 8, 1686.
  93. Almeida, J.F.M.; Peres, K.C.; Teixeira, E.S.; Teodoro, L.; Bó, I.F.D.; Ward, L.S. Epstein-Barr Virus and Thyroid Cancer. Crit. Rev. Oncog. 2019, 24, 369–377.
  94. Jenson, H.B. Epstein-Barr Virus. Pediatr. Rev. 2011, 32, 375–383.
  95. Faulkner, G.C.; Krajewski, A.S.; Crawford, D.H. The Ins and Outs of EBV Infection. Trends Microbiol. 2000, 8, 185–189.
  96. Szymula, A.; Palermo, R.D.; Bayoumy, A.; Groves, I.J.; Ba Abdullah, M.; Holder, B.; White, R.E. Epstein-Barr Virus Nuclear Antigen EBNA-LP Is Essential for Transforming Naïve B Cells, and Facilitates Recruitment of Transcription Factors to the Viral Genome. PLoS Pathog. 2018, 14, e1006890.
  97. Cohen, J.I. Epstein-Barr Virus Infection. N. Engl. J. Med. 2000, 343, 481–492.
  98. Smedby, K.E.; Ponzoni, M. The Aetiology of B-Cell Lymphoid Malignancies with a Focus on Chronic Inflammation and Infections. J. Intern. Med. 2017, 282, 360–370.
  99. Mawson, A.R.; Majumdar, S. Malaria, Epstein–Barr Virus Infection and the Pathogenesis of Burkitt’s Lymphoma. Int. J. Cancer 2017, 141, 1849–1855.
  100. Saha, A.; Robertson, E.S. Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus. J. Virol. 2019, 93, e00238-19.
  101. Yoshizaki, T.; Kondo, S.; Endo, K.; Nakanishi, Y.; Aga, M.; Kobayashi, E.; Hirai, N.; Sugimoto, H.; Hatano, M.; Ueno, T.; et al. Modulation of the Tumor Microenvironment by Epstein-Barr Virus Latent Membrane Protein 1 in Nasopharyngeal Carcinoma. Cancer Sci. 2018, 109, 272–278.
  102. Liu, W.; Song, Y.; Wang, J.; Xiao, H.; Zhang, Y.; Luo, B. Dysregulation of FOXO Transcription Factors in Epstein-Barr Virus-Associated Gastric Carcinoma. Virus Res. 2020, 276, 197808.
  103. Tsao, S.W.; Tsang, C.M.; Lo, K.W. Epstein-Barr Virus Infection and Nasopharyngeal Carcinoma. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2017, 372, 20160270.
  104. Gong, L.; Chen, J.; Dong, M.; Xiao, Z.; Feng, Z.; Pan, Y.; Zhang, Y.; Du, Y.; Zhang, J.; Bi, Y.; et al. Epstein–Barr Virus-Derived Circular RNA LMP2A Induces Stemness in EBV-Associated Gastric Cancer. EMBO Rep. 2020, 21, e49689.
  105. Tsai, M.-H.; Lin, X.; Shumilov, A.; Bernhardt, K.; Feederle, R.; Poirey, R.; Kopp-Schneider, A.; Pereira, B.; Almeida, R.; Delecluse, H.-J. The Biological Properties of Different Epstein-Barr Virus Strains Explain Their Association with Various Types of Cancers. Oncotarget 2017, 8, 10238–10254.
  106. Kim, H.-J.; Ko, Y.H.; Kim, J.E.; Lee, S.-S.; Lee, H.; Park, G.; Paik, J.H.; Cha, H.J.; Choi, Y.-D.; Han, J.H.; et al. Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. J. Pathol. Transl. Med. 2017, 51, 352–358.
  107. Saleem, A.; Natkunam, Y. Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. Int. J. Mol. Sci. 2020, 21, 1501.
  108. Song, H.; Lim, Y.; Im, H.; Bae, J.M.; Kang, G.H.; Ahn, J.; Baek, D.; Kim, T.-Y.; Yoon, S.-S.; Koh, Y. Interpretation of EBV Infection in Pan-Cancer Genome Considering Viral Life Cycle: LiEB (Life Cycle of Epstein-Barr Virus). Sci. Rep. 2019, 9, 3465.
  109. Miller, C.M.; Selvam, S.; Fuchs, G. Fatal Attraction: The Roles of Ribosomal Proteins in the Viral Life Cycle. WIREs RNA 2020, 12, e1613.
  110. Scott, R.S. Epstein–Barr Virus: A Master Epigenetic Manipulator. Eng. Viral Resist. Viruses Cancer 2017, 26, 74–80.
  111. Thorley-Lawson, D.A. EBV Persistence—Introducing the Virus. In Epstein Barr Virus Volume 1: One Herpes Virus: Many Diseases; Münz, C., Ed.; Springer International Publishing: Cham, Switzerland, 2015; pp. 151–209. ISBN 978-3-319-22822-8.
  112. Kang, M.-S.; Kieff, E. Epstein–Barr Virus Latent Genes. Exp. Mol. Med. 2015, 47, e131.
  113. Choi, S.J.; Shin, Y.S.; Kang, B.W.; Kim, J.G.; Won, K.-J.; Lieberman, P.M.; Cho, H.; Kang, H. DNA Hypermethylation Induced by Epstein-Barr Virus in the Development of Epstein-Barr Virus-Associated Gastric Carcinoma. Arch. Pharm. Res. 2017, 40, 894–905.
  114. Shannon-Lowe, C.; Rickinson, A. The Global Landscape of EBV-Associated Tumors. Front. Oncol. 2019, 9, 713.
  115. Hughes, D.J.; Marendy, E.M.; Dickerson, C.A.; Yetming, K.D.; Sample, C.E.; Sample, J.T. Contributions of CTCF and DNA Methyltransferases DNMT1 and DNMT3B to Epstein-Barr Virus Restricted Latency. J. Virol. 2012, 86, 1034–1045.
  116. Anderton, J.A.; Bose, S.; Vockerodt, M.; Vrzalikova, K.; Wei, W.; Kuo, M.; Helin, K.; Christensen, J.; Rowe, M.; Murray, P.G.; et al. The H3K27me3 Demethylase, KDM6B, Is Induced by Epstein–Barr Virus and over-Expressed in Hodgkin’s Lymphoma. Oncogene 2011, 30, 2037–2043.
  117. Hino, R.; Uozaki, H.; Murakami, N.; Ushiku, T.; Shinozaki, A.; Ishikawa, S.; Morikawa, T.; Nakaya, T.; Sakatani, T.; Takada, K.; et al. Activation of DNA Methyltransferase 1 by EBV Latent Membrane Protein 2A Leads to Promoter Hypermethylation of PTEN Gene in Gastric Carcinoma. Cancer Res. 2009, 69, 2766.
  118. Lu, F.; Wiedmer, A.; Martin, K.A.; Wickramasinghe, P.J.M.S.; Kossenkov, A.V.; Lieberman, P.M. Coordinate Regulation of TET2 and EBNA2 Controls the DNA Methylation State of Latent Epstein-Barr Virus. J. Virol. 2017, 91, e00804-17.
  119. Wille, C.K.; Li, Y.; Rui, L.; Johannsen, E.C.; Kenney, S.C. Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency. J. Virol. 2017, 91, e01987-16.
  120. Radkov, S.A.; Touitou, R.; Brehm, A.; Rowe, M.; West, M.; Kouzarides, T.; Allday, M.J. Epstein-Barr Virus Nuclear Antigen 3C Interacts with Histone Deacetylase to Repress Transcription. J. Virol. 1999, 73, 5688–5697.
  121. McClellan, M.J.; Wood, C.D.; Ojeniyi, O.; Cooper, T.J.; Kanhere, A.; Arvey, A.; Webb, H.M.; Palermo, R.D.; Harth-Hertle, M.L.; Kempkes, B.; et al. Modulation of Enhancer Looping and Differential Gene Targeting by Epstein-Barr Virus Transcription Factors Directs Cellular Reprogramming. PLoS Pathog. 2013, 9, e1003636.
  122. Wood, C.D.; Veenstra, H.; Khasnis, S.; Gunnell, A.; Webb, H.M.; Shannon-Lowe, C.; Andrews, S.; Osborne, C.S.; West, M.J. MYC Activation and BCL2L11 Silencing by a Tumour Virus through the Large-Scale Reconfiguration of Enhancer-Promoter Hubs. eLife 2016, 5, e18270.
  123. Zhang, W. TCGA Divides Gastric Cancer into Four Molecular Subtypes: Implications for Individualized Therapeutics. Chin. J. Cancer 2014, 33, 469–470.
  124. Gulley, M.L. Genomic Assays for Epstein-Barr Virus-Positive Gastric Adenocarcinoma. Exp. Mol. Med. 2015, 47, e134.
  125. Soldan, S.S.; Anderson, E.M.; Frase, D.M.; Zhang, Y.; Caruso, L.B.; Wang, Y.; Deakyne, J.S.; Gewurz, B.E.; Tempera, I.; Lieberman, P.M.; et al. EBNA1 Inhibitors Have Potent and Selective Antitumor Activity in Xenograft Models of Epstein–Barr Virus-Associated Gastric Cancer. Gastric Cancer 2021.
  126. Fiches, G.N.; Zhou, D.; Kong, W.; Biswas, A.; Ahmed, E.H.; Baiocchi, R.A.; Zhu, J.; Santoso, N. Profiling of Immune Related Genes Silenced in EBV-Positive Gastric Carcinoma Identified Novel Restriction Factors of Human Gammaherpesviruses. PLoS Pathog. 2020, 16, e1008778.
  127. Zheng, X.-H.; Wang, R.-Z.; Li, X.-Z.; Zhou, T.; Zhang, J.-B.; Zhang, P.-F.; Lu, L.-X.; Jia, W.-H. Detection of Methylation Status of Epstein-Barr Virus DNA C Promoter in the Diagnosis of Nasopharyngeal Carcinoma. Cancer Sci. 2020, 111, 592–600.
  128. Lu, F.; Martin, K.A.; Soldan, S.S.; Kossenkov, A.V.; Wickramasinghe, P.; Vladimirova, O.; De Leo, A.; Lin, C.; Nefedova, Y.; Lieberman, P.M. Defective Epstein-Barr Virus Genomes and Atypical Viral Gene Expression in B-Cell Lines Derived from Multiple Myeloma Patients. J. Virol. 2021.
  129. Lavanchy, D. Hepatitis B Virus Epidemiology, Disease Burden, Treatment, and Current and Emerging Prevention and Control Measures. J. Viral Hepat. 2004, 11, 97–107.
  130. Seeger, C.; Mason, W.S. Molecular Biology of Hepatitis B Virus Infection. Virology 2015, 479–480, 672–686.
  131. Yang, B.; Li, B.; Jia, L.; Jiang, Y.; Wang, X.; Jiang, S.; Du, S.; Ji, X.; Yang, P. 3D Landscape of Hepatitis B Virus Interactions with Human Chromatins. Cell Discov. 2020, 6, 95.
  132. Park, I.Y.; Sohn, B.H.; Yu, E.; Suh, D.J.; Chung, Y.; Lee, J.; Surzycki, S.J.; Lee, Y.I. Aberrant Epigenetic Modifications in Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein. Gastroenterology 2007, 132, 1476–1494.
  133. Kuss-Duerkop, S.K.; Westrich, J.A.; Pyeon, D. DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis. Viruses 2018, 10, 82.
  134. Zheng, D.-L.; Zhang, L.; Cheng, N.; Xu, X.; Deng, Q.; Teng, X.-M.; Wang, K.-S.; Zhang, X.; Huang, J.; Han, Z.-G. Epigenetic Modification Induced by Hepatitis B Virus X Protein via Interaction with de Novo DNA Methyltransferase DNMT3A. J. Hepatol. 2009, 50, 377–387.
  135. Um, T.-H.; Kim, H.; Oh, B.-K.; Kim, M.S.; Kim, K.S.; Jung, G.; Park, Y.N. Aberrant CpG Island Hypermethylation in Dysplastic Nodules and Early HCC of Hepatitis B Virus-Related Human Multistep Hepatocarcinogenesis. J. Hepatol. 2011, 54, 939–947.
  136. Li, H.; Yang, F.; Gao, B.; Yu, Z.; Liu, X.; Xie, F.; Zhang, J. Hepatitis B Virus Infection in Hepatocellular Carcinoma Tissues Upregulates Expression of DNA Methyltransferases. Int. J. Clin. Exp. Med. 2015, 8, 4175–4185.
  137. Jung, J.K.; Arora, P.; Pagano, J.S.; Jang, K.L. Expression of DNA Methyltransferase 1 Is Activated by Hepatitis B Virus X Protein via a Regulatory Circuit Involving the P16INK4a-Cyclin D1-CDK 4/6-PRb-E2F1 Pathway. Cancer Res. 2007, 67, 5771.
  138. Hesson, L.B.; Cooper, W.N.; Latif, F. The Role of RASSF1A Methylation in Cancer. Dis. Markers 2007, 23, 73–87.
  139. Pogribny, I.P.; Rusyn, I. Role of Epigenetic Aberrations in the Development and Progression of Human Hepatocellular Carcinoma. Cancer Lett. 2014, 342, 223–230.
  140. Yuan, K.; Lei, Y.; Chen, H.-N.; Chen, Y.; Zhang, T.; Li, K.; Xie, N.; Wang, K.; Feng, X.; Pu, Q.; et al. HBV-Induced ROS Accumulation Promotes Hepatocarcinogenesis through Snail-Mediated Epigenetic Silencing of SOCS3. Cell Death Differ. 2016, 23, 616–627.
  141. Yu, H.; Pardoll, D.; Jove, R. STATs in Cancer Inflammation and Immunity: A Leading Role for STAT3. Nat. Rev. Cancer 2009, 9, 798–809.
  142. Yasukawa, H.; Ohishi, M.; Mori, H.; Murakami, M.; Chinen, T.; Aki, D.; Hanada, T.; Takeda, K.; Akira, S.; Hoshijima, M.; et al. IL-6 Induces an Anti-Inflammatory Response in the Absence of SOCS3 in Macrophages. Nat. Immunol. 2003, 4, 551–556.
  143. Song, G.; Zhu, X.; Xuan, Z.; Zhao, L.; Dong, H.; Chen, J.; Li, Z.; Song, W.; Jin, C.; Zhou, M.; et al. Hypermethylation of GNA14 and Its Tumor-Suppressive Role in Hepatitis B Virus-Related Hepatocellular Carcinoma. Theranostics 2021, 11, 2318–2333.
  144. Lee, S.-M.; Lee, Y.; Bae, J.-B.; Choi, J.K.; Tayama, C.; Hata, K.; Yun, Y.; Seong, J.-K.; Kim, Y.-J. HBx Induces Hypomethylation of Distal Intragenic CpG Islands Required for Active Expression of Developmental Regulators. Proc. Natl. Acad. Sci. USA 2014, 111.
  145. Yue, X.; Yang, F.; Yang, Y.; Mu, Y.; Sun, W.; Li, W.; Xu, D.; Wu, J.; Zhu, Y. Induction of Cyclooxygenase-2 Expression by Hepatitis B Virus Depends on Demethylation-Associated Recruitment of Transcription Factors to the Promoter. Virol. J. 2011, 8, 118.
  146. Fan, H.; Zhang, H.; Pascuzzi, P.E.; Andrisani, O. Hepatitis B Virus X Protein Induces EpCAM Expression via Active DNA Demethylation Directed by RelA in Complex with EZH2 and TET2. Oncogene 2016, 35, 715–726.
  147. Neri, F.; Krepelova, A.; Incarnato, D.; Maldotti, M.; Parlato, C.; Galvagni, F.; Matarese, F.; Stunnenberg, H.G.; Oliviero, S. Dnmt3L Antagonizes DNA Methylation at Bivalent Promoters and Favors DNA Methylation at Gene Bodies in ESCs. Cell 2013, 155, 121–134.
  148. Gao, W.; Jia, Z.; Tian, Y.; Yang, P.; Sun, H.; Wang, C.; Ding, Y.; Zhang, M.; Zhang, Y.; Yang, D.; et al. HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein. Hepatology 2020, 71, 1678–1695.
  149. Salerno, D.; Chiodo, L.; Alfano, V.; Floriot, O.; Cottone, G.; Paturel, A.; Pallocca, M.; Plissonnier, M.-L.; Jeddari, S.; Belloni, L.; et al. Hepatitis B Protein HBx Binds the DLEU2 LncRNA to Sustain CccDNA and Host Cancer-Related Gene Transcription. Gut 2020, 69, 2016–2024.
  150. Cougot, D.; Wu, Y.; Cairo, S.; Caramel, J.; Renard, C.-A.; Lévy, L.; Buendia, M.A.; Neuveut, C. The Hepatitis B Virus X Protein Functionally Interacts with CREB-Binding Protein/P300 in the Regulation of CREB-Mediated Transcription. J. Biol. Chem. 2007, 282, 4277–4287.
  151. Decorsière, A.; Mueller, H.; van Breugel, P.C.; Abdul, F.; Gerossier, L.; Beran, R.K.; Livingston, C.M.; Niu, C.; Fletcher, S.P.; Hantz, O.; et al. Hepatitis B Virus X Protein Identifies the Smc5/6 Complex as a Host Restriction Factor. Nature 2016, 531, 386–389.
  152. Mitra, B.; Guo, H. Hepatitis B Virus X Protein Crosses out Smc5/6 Complex to Maintain Covalently Closed Circular DNA Transcription. Hepatology 2016, 64, 2246–2249.
  153. Abdul, F.; Filleton, F.; Gerossier, L.; Paturel, A.; Hall, J.; Strubin, M.; Etienne, L. Smc5/6 Antagonism by HBx Is an Evolutionarily Conserved Function of Hepatitis B Virus Infection in Mammals. J. Virol. 2018, 92.
  154. Murphy, C.M.; Xu, Y.; Li, F.; Nio, K.; Reszka-Blanco, N.; Li, X.; Wu, Y.; Yu, Y.; Xiong, Y.; Su, L. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep. 2016, 16, 2846–2854.
  155. Allweiss, L.; Giersch, K.; Pirosu, A.; Volz, T.; Muench, R.C.; Beran, R.K.; Urban, S.; Javanbakht, H.; Fletcher, S.P.; Lütgehetmann, M.; et al. Therapeutic Shutdown of HBV Transcripts Promotes Reappearance of the SMC5/6 Complex and Silencing of the Viral Genome in Vivo. Gut 2021.
  156. Niu, C.; Livingston, C.M.; Li, L.; Beran, R.K.; Daffis, S.; Ramakrishnan, D.; Burdette, D.; Peiser, L.; Salas, E.; Ramos, H.; et al. The Smc5/6 Complex Restricts HBV When Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PLoS ONE 2017, 12, e0169648.
  157. Rivera-Molina, Y.A.; Martínez, F.P.; Tang, Q. Nuclear Domain 10 of the Viral Aspect. World J. Virol. 2013, 2, 110–122.
  158. Andrisani, O.M. Deregulation of Epigenetic Mechanisms by the Hepatitis B Virus X Protein in Hepatocarcinogenesis. Viruses 2013, 5, 858–872.
  159. Jacome, A.; Gutierrez-Martinez, P.; Schiavoni, F.; Tenaglia, E.; Martinez, P.; Rodríguez-Acebes, S.; Lecona, E.; Murga, M.; Méndez, J.; Blasco, M.A.; et al. NSMCE2 Suppresses Cancer and Aging in Mice Independently of Its SUMO Ligase Activity. EMBO J. 2015, 34, 2604–2619.
  160. Guo, Y.; Kang, W.; Lei, X.; Li, Y.; Xiang, A.; Liu, Y.; Zhao, J.; Zhang, J.; Yan, Z. Hepatitis B Viral Core Protein Disrupts Human Host Gene Expression by Binding to Promoter Regions. BMC Genom. 2012, 13, 563.
  161. Moreau, P.; Cournac, A.; Palumbo, G.A.; Marbouty, M.; Mortaza, S.; Thierry, A.; Cairo, S.; Lavigne, M.; Koszul, R.; Neuveut, C. Tridimensional Infiltration of DNA Viruses into the Host Genome Shows Preferential Contact with Active Chromatin. Nat. Commun. 2018, 9, 4268.
  162. Magalhães, G.M.; Vieira, É.C.; Garcia, L.C.; Carvalho-Leite, D.; de Lourdes Ribeiro, M.; Guedes, A.C.M.; Araújo, M.G. Update on Human Papilloma Virus—Part I: Epidemiology, Pathogenesis, and Clinical Spectrum. An. Bras. Dermatol. 2021, 96, 1–16.
  163. de Martel, C.; Plummer, M.; Vignat, J.; Franceschi, S. Worldwide Burden of Cancer Attributable to HPV by Site, Country and HPV Type. Int. J. Cancer 2017, 141, 664–670.
  164. Bernard, H.-U.; Burk, R.D.; Chen, Z.; van Doorslaer, K.; zur Hausen, H.; de Villiers, E.-M. Classification of Papillomaviruses (PVs) Based on 189 PV Types and Proposal of Taxonomic Amendments. Virology 2010, 401, 70–79.
  165. Schwarz, E.; Freese, U.K.; Gissmann, L.; Mayer, W.; Roggenbuck, B.; Stremlau, A.; Hausen, H. zur Structure and Transcription of Human Papillomavirus Sequences in Cervical Carcinoma Cells. Nature 1985, 314, 111–114.
  166. Baker, C.C.; Phelps, W.C.; Lindgren, V.; Braun, M.J.; Gonda, M.A.; Howley, P.M. Structural and Transcriptional Analysis of Human Papillomavirus Type 16 Sequences in Cervical Carcinoma Cell Lines. J. Virol. 1987, 61, 962–971.
  167. Doorbar, J.; Egawa, N.; Griffin, H.; Kranjec, C.; Murakami, I. Human Papillomavirus Molecular Biology and Disease Association. Rev. Med. Virol. 2015, 25 (Suppl. 1), 2–23.
  168. McPhillips, M.G.; Ozato, K.; McBride, A.A. Interaction of Bovine Papillomavirus E2 Protein with Brd4 Stabilizes Its Association with Chromatin. J. Virol. 2005, 79, 8920.
  169. Bellanger, S.; Tan, C.L.; Xue, Y.Z.; Teissier, S.; Thierry, F. Tumor Suppressor or Oncogene? A Critical Role of the Human Papillomavirus (HPV) E2 Protein in Cervical Cancer Progression. Am. J. Cancer Res. 2011, 1, 373–389.
  170. Akagi, K.; Li, J.; Broutian, T.R.; Padilla-Nash, H.; Xiao, W.; Jiang, B.; Rocco, J.W.; Teknos, T.N.; Kumar, B.; Wangsa, D.; et al. Genome-Wide Analysis of HPV Integration in Human Cancers Reveals Recurrent, Focal Genomic Instability. Genome Res. 2014, 24, 185–199.
  171. Thierry, F.; Yaniv, M. The BPV1-E2 Trans-Acting Protein Can Be Either an Activator or a Repressor of the HPV18 Regulatory Region. EMBO J. 1987, 6, 3391–3397.
  172. Garnett, T.O.; Duerksen-Hughes, P.J. Modulation of Apoptosis by Human Papillomavirus (HPV) Oncoproteins. Arch. Virol. 2006, 151, 2321–2335.
  173. Jiang, P.; Yue, Y. Human Papillomavirus Oncoproteins and Apoptosis (Review). Exp. Ther. Med. 2014, 7, 3–7.
  174. Hellner, K.; Münger, K. Human Papillomaviruses as Therapeutic Targets in Human Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29, 1785–1794.
  175. Venuti, A.; Paolini, F.; Nasir, L.; Corteggio, A.; Roperto, S.; Campo, M.S.; Borzacchiello, G. Papillomavirus E5: The Smallest Oncoprotein with Many Functions. Mol. Cancer 2011, 10, 140.
  176. Yugawa, T.; Kiyono, T. Molecular Mechanisms of Cervical Carcinogenesis by High-Risk Human Papillomaviruses: Novel Functions of E6 and E7 Oncoproteins. Rev. Med. Virol. 2009, 19, 97–113.
  177. Badal, V.; Chuang, L.S.H.; Tan, E.H.-H.; Badal, S.; Villa, L.L.; Wheeler, C.M.; Li, B.F.L.; Bernard, H.-U. CpG Methylation of Human Papillomavirus Type 16 DNA in Cervical Cancer Cell Lines and in Clinical Specimens: Genomic Hypomethylation Correlates with Carcinogenic Progression. J. Virol. 2003, 77, 6227–6234.
  178. McLaughlin-Drubin, M.E.; Munger, K. Biochemical and Functional Interactions of Human Papillomavirus Proteins with Polycomb Group Proteins. Viruses 2013, 5, 1231–1249.
  179. Hsu, C.-H.; Peng, K.-L.; Jhang, H.-C.; Lin, C.-H.; Wu, S.-Y.; Chiang, C.-M.; Lee, S.-C.; Yu, W.C.Y.; Juan, L.-J. The HPV E6 Oncoprotein Targets Histone Methyltransferases for Modulating Specific Gene Transcription. Oncogene 2012, 31, 2335–2349.
  180. Li, S.; Hong, X.; Wei, Z.; Xie, M.; Li, W.; Liu, G.; Guo, H.; Yang, J.; Wei, W.; Zhang, S. Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated P53 Degradation. Front. Microbiol. 2019, 10, 2483.
  181. Thomas, M.C.; Chiang, C.-M. E6 Oncoprotein Represses P53-Dependent Gene Activation via Inhibition of Protein Acetylation Independently of Inducing P53 Degradation. Mol. Cell 2005, 17, 251–264.
  182. Jansma, A.L.; Martinez-Yamout, M.A.; Liao, R.; Sun, P.; Dyson, H.J.; Wright, P.E. The High-Risk HPV16 E7 Oncoprotein Mediates Interaction between the Transcriptional Coactivator CBP and the Retinoblastoma Protein PRb. J. Mol. Biol. 2014, 426, 4030–4048.
  183. Huang, S.-M.; McCance, D.J. Down Regulation of the Interleukin-8 Promoter by Human Papillomavirus Type 16 E6 and E7 through Effects on CREB Binding Protein/P300 and P/CAF. J. Virol. 2002, 76, 8710–8721.
  184. Bodily, J.M.; Mehta, K.P.M.; Laimins, L.A. Human Papillomavirus E7 Enhances Hypoxia-inducible Factor 1-mediated Transcription by Inhibiting Binding of Histone Deacetylases. Cancer Res. 2010, 71, 1187–1195.
  185. McLaughlin-Drubin, M.E.; Crum, C.P.; Münger, K. Human Papillomavirus E7 Oncoprotein Induces KDM6A and KDM6B Histone Demethylase Expression and Causes Epigenetic Reprogramming. Proc. Natl. Acad. Sci. USA 2011, 108, 2130.
  186. McLaughlin-Drubin, M.E.; Park, D.; Munger, K. Tumor Suppressor P16INK4A Is Necessary for Survival of Cervical Carcinoma Cell Lines. Proc. Natl. Acad. Sci. USA 2013, 110.
  187. Ishida, K.; Tomita, H.; Kanayama, T.; Noguchi, K.; Niwa, A.; Kawaguchi, M.; Miyai, M.; Matsuo, M.; Imaizumi, Y.; Kato, K.; et al. Specific Deletion of P16INK4a with Retention of P19ARF Enhances the Development of Invasive Oral Squamous Cell Carcinoma. Am. J. Pathol. 2020, 190, 1332–1342.
  188. Tam, K.W.; Zhang, W.; Soh, J.; Stastny, V.; Chen, M.; Sun, H.; Thu, K.; Rios, J.J.; Yang, C.; Marconett, C.N.; et al. CDKN2A/P16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non-Small-Cell Lung Cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2013, 8, 1378–1388.
  189. Ming, Z.; Lim, S.Y.; Rizos, H. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression. Biomolecules 2020, 10, 1447.
  190. Huh, K.; Zhou, X.; Hayakawa, H.; Cho, J.-Y.; Libermann, T.A.; Jin, J.; Harper, J.W.; Munger, K. Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Cullin 2 Ubiquitin Ligase Complex, Which Contributes to Degradation of the Retinoblastoma Tumor Suppressor. J. Virol. 2007, 81, 9737–9747.
  191. Munger, K.; Gwin, T.K.; McLaughlin-Drubin, M.E. P16 in HPV-Associated Cancers. Oncotarget 2013, 4, 1864–1865.
  192. Kanao, H.; Enomoto, T.; Ueda, Y.; Fujita, M.; Nakashima, R.; Ueno, Y.; Miyatake, T.; Yoshizaki, T.; Buzard, G.S.; Kimura, T.; et al. Correlation between P14ARF/P16INK4A Expression and HPV Infection in Uterine Cervical Cancer. Cancer Lett. 2004, 213, 31–37.
  193. Quinonez, S.C.; Innis, J.W. Human HOX Gene Disorders. Mol. Genet. Metab. 2014, 111, 4–15.
  194. Hock, H. A Complex Polycomb Issue: The Two Faces of EZH2 in Cancer. Genes Dev. 2012, 26, 751–755.
  195. Hyland, P.L.; McDade, S.S.; McCloskey, R.; Dickson, G.J.; Arthur, K.; McCance, D.J.; Patel, D. Evidence for Alteration of EZH2, BMI1, and KDM6A and Epigenetic Reprogramming in Human Papillomavirus Type 16 E6/E7-Expressing Keratinocytes. J. Virol. 2011, 85, 10999–11006.
  196. Kuzmichev, A.; Margueron, R.; Vaquero, A.; Preissner, T.S.; Scher, M.; Kirmizis, A.; Ouyang, X.; Brockdorff, N.; Abate-Shen, C.; Farnham, P.; et al. Composition and Histone Substrates of Polycomb Repressive Group Complexes Change during Cellular Differentiation. Proc. Natl. Acad. Sci. USA 2005, 102, 1859.
  197. Liu, T.F.; McCall, C.E. Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer 2013, 4, 135–147.
  198. Jing, H.; Lin, H. Sirtuins in Epigenetic Regulation. Chem. Rev. 2015, 115, 2350–2375.
  199. Brock, M.V.; Herman, J.G.; Baylin, S.B. Cancer as a Manifestation of Aberrant Chromatin Structure. Cancer J. 2007, 13, 3.
  200. Hwang, S.G.; Lee, D.; Kim, J.; Seo, T.; Choe, J. Human Papillomavirus Type 16 E7 Binds to E2F1 and Activates E2F1-Driven Transcription in a Retinoblastoma Protein-Independent Manner. J. Biol. Chem. 2002, 277, 2923–2930.
  201. Lyons, T.E.; Salih, M.; Tuana, B.S. Activating E2Fs Mediate Transcriptional Regulation of Human E2F6 Repressor. Am. J. Physiol. 2006, 290, C189–C199.
  202. McLaughlin-Drubin, M.E.; Münger, K. The Human Papillomavirus E7 Oncoprotein. Virology 2009, 384, 335–344.
  203. Ren, S.; Gaykalova, D.A.; Guo, T.; Favorov, A.V.; Fertig, E.J.; Tamayo, P.; Callejas-Valera, J.L.; Allevato, M.; Gilardi, M.; Santos, J.; et al. HPV E2, E4, E5 Drive Alternative Carcinogenic Pathways in HPV Positive Cancers. Oncogene 2020, 39, 6327–6339.
  204. Moll, I.; Roessler, M.; Brandner, J.M.; Eispert, A.-C.; Houdek, P.; Moll, R. Human Merkel Cells—Aspects of Cell Biology, Distribution and Functions. Eur. J. Cell Biol. 2005, 84, 259–271.
  205. Halata, Z.; Grim, M.; Bauman, K.I. Friedrich Sigmund Merkel and His “Merkel Cell”, Morphology, Development, and Physiology: Review and New Results. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 2003, 271A, 225–239.
  206. Toker, C. Trabecular Carcinoma of the Skin. Arch. Dermatol. 1972, 105, 107–110.
  207. Hodgson, N.C. Merkel Cell Carcinoma: Changing Incidence Trends. J. Surg. Oncol. 2005, 89, 1–4.
  208. Andres, C.; Belloni, B.; Puchta, U.; Sander, C.A.; Flaig, M.J. Prevalence of MCPyV in Merkel Cell Carcinoma and Non-MCC Tumors. J. Cutan. Pathol. 2010, 37, 28–34.
  209. Becker, J.C.; Stang, A.; DeCaprio, J.A.; Cerroni, L.; Lebbé, C.; Veness, M.; Nghiem, P. Merkel Cell Carcinoma. Nat. Rev. Dis. Primer 2017, 3, 17077.
  210. Houben, R.; Schrama, D.; Becker, J.C. Molecular Pathogenesis of Merkel Cell Carcinoma. Exp. Dermatol. 2009, 18, 193–198.
  211. White, M.K.; Gordon, J.; Khalili, K. The Rapidly Expanding Family of Human Polyomaviruses: Recent Developments in Understanding Their Life Cycle and Role in Human Pathology. PLoS Pathog. 2013, 9, e1003206.
  212. Kwun, H.J.; Chang, Y.; Moore, P.S. Protein-Mediated Viral Latency Is a Novel Mechanism for Merkel Cell Polyomavirus Persistence. Proc. Natl. Acad. Sci. USA 2017, 114, E4040.
  213. Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma. Science 2008, 319, 1096–1100.
  214. Cheng, J.; Rozenblatt-Rosen, O.; Paulson, K.G.; Nghiem, P.; DeCaprio, J.A. Merkel Cell Polyomavirus Large T Antigen Has Growth Promoting and Inhibitory Activities. J. Virol. 2013.
  215. Verhaegen, M.E.; Mangelberger, D.; Harms, P.W.; Vozheiko, T.D.; Weick, J.W.; Wilbert, D.M.; Saunders, T.L.; Ermilov, A.N.; Bichakjian, C.K.; Johnson, T.M.; et al. Merkel Cell Polyomavirus Small T Antigen Is Oncogenic in Transgenic Mice. J. Investig. Dermatol. 2015, 135, 1415–1424.
  216. Czech-Sioli, M.; Günther, T.; Therre, M.; Spohn, M.; Indenbirken, D.; Theiss, J.; Riethdorf, S.; Qi, M.; Alawi, M.; Wülbeck, C.; et al. High-Resolution Analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma Reveals Distinct Integration Patterns and Suggests NHEJ and MMBIR as Underlying Mechanisms. PLoS Pathog. 2020, 16, e1008562.
  217. Moore, P.S.; Chang, Y. Why Do Viruses Cause Cancer? Highlights of the First Century of Human Tumour Virology. Nat. Rev. Cancer 2010, 10, 878–889.
  218. Schrama, D.; Sarosi, E.-M.; Adam, C.; Ritter, C.; Kaemmerer, U.; Klopocki, E.; König, E.-M.; Utikal, J.; Becker, J.C.; Houben, R. Characterization of Six Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Lines: Integration Pattern Suggest That Large T Antigen Truncating Events Occur before or during Integration. Int. J. Cancer 2019, 145, 1020–1032.
  219. Martel-Jantin, C.; Filippone, C.; Cassar, O.; Peter, M.; Tomasic, G.; Vielh, P.; Brière, J.; Petrella, T.; Aubriot-Lorton, M.H.; Mortier, L.; et al. Genetic Variability and Integration of Merkel Cell Polyomavirus in Merkel Cell Carcinoma. Virology 2012, 426, 134–142.
  220. Harms, P.W.; Harms, K.L.; Moore, P.S.; DeCaprio, J.A.; Nghiem, P.; Wong, M.K.K.; Brownell, I.; on behalf of the International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group. The Biology and Treatment of Merkel Cell Carcinoma: Current Understanding and Research Priorities. Nat. Rev. Clin. Oncol. 2018, 15, 763–776.
  221. Arora, R.; Choi, J.E.; Harms, P.W.; Chandrani, P. Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene. Viruses 2020, 12, 966.
  222. Park, D.E.; Cheng, J.; McGrath, J.P.; Lim, M.Y.; Cushman, C.; Swanson, S.K.; Tillgren, M.L.; Paulo, J.A.; Gokhale, P.C.; Florens, L.; et al. Merkel Cell Polyomavirus Activates LSD1-Mediated Blockade of Non-Canonical BAF to Regulate Transformation and Tumorigenesis. Nat. Cell Biol. 2020, 22, 603–615.
  223. Dauber, K.L.; Perdigoto, C.N.; Valdes, V.J.; Santoriello, F.J.; Cohen, I.; Ezhkova, E. Dissecting the Roles of Polycomb Repressive Complex 2 Subunits in the Control of Skin Development. J. Investig. Dermatol. 2016, 136, 1647–1655.
  224. Perdigoto, C.N.; Dauber, K.L.; Bar, C.; Tsai, P.-C.; Valdes, V.J.; Cohen, I.; Santoriello, F.J.; Zhao, D.; Zheng, D.; Hsu, Y.-C.; et al. Polycomb-Mediated Repression and Sonic Hedgehog Signaling Interact to Regulate Merkel Cell Specification during Skin Development. PLoS Genet. 2016, 12, e1006151.
  225. Botchkarev, V.A.; Mardaryev, A.N. Repressing the Keratinocyte Genome: How the Polycomb Complex Subunits Operate in Concert to Control Skin and Hair Follicle Development. J. Investig. Dermatol. 2016, 136, 1538–1540.
  226. Busam, K.J.; Pulitzer, M.P.; Coit, D.C.; Arcila, M.; Leng, D.; Jungbluth, A.A.; Wiesner, T. Reduced H3K27me3 Expression in Merkel Cell Polyoma Virus-Positive Tumors. Mod. Pathol. 2017, 30, 877–883.
  227. Wiles, E.T.; Selker, E.U. H3K27 Methylation: A Promiscuous Repressive Chromatin Mark. Genome Archit. Expr. 2017, 43, 31–37.
  228. Morgan, M.A.J.; Shilatifard, A. Reevaluating the Roles of Histone-Modifying Enzymes and Their Associated Chromatin Modifications in Transcriptional Regulation. Nat. Genet. 2020, 52, 1271–1281.
  229. Harms, K.L.; Chubb, H.; Zhao, L.; Fullen, D.R.; Bichakjian, C.K.; Johnson, T.M.; Carskadon, S.; Palanisamy, N.; Harms, P.W. Increased Expression of EZH2 in Merkel Cell Carcinoma Is Associated with Disease Progression and Poorer Prognosis. Hum. Pathol. 2017, 67, 78–84.
  230. Ganem, D. KSHV and the Pathogenesis of Kaposi Sarcoma: Listening to Human Biology and Medicine. J. Clin. Investig. 2010, 120, 939–949.
  231. Horenstein, M.G.; Moontasri, N.J.; Cesarman, E. The Pathobiology of Kaposi’s Sarcoma: Advances since the Onset of the AIDS Epidemic. J. Cutan. Pathol. 2008, 35, 40–44.
  232. Gramolelli, S.; Schulz, T.F. The Role of Kaposi Sarcoma-Associated Herpesvirus in the Pathogenesis of Kaposi Sarcoma. J. Pathol. 2015, 235, 368–380.
  233. Dourmishev, L.A.; Dourmishev, A.L.; Palmeri, D.; Schwartz, R.A.; Lukac, D.M. Molecular Genetics of Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev. 2003, 67, 175–212.
  234. Taylor, G.S.; Blackbourn, D.J. Infectious Agents in Human Cancers: Lessons in Immunity and Immunomodulation from Gammaherpesviruses EBV and KSHV. Cancer Lett. 2011, 305, 263–278.
  235. Aresté, C.; Blackbourn, D.J. Modulation of the Immune System by Kaposi’s Sarcoma-Associated Herpesvirus. Trends Microbiol. 2009, 17, 119–129.
  236. Godden-Kent, D.; Talbot, S.J.; Boshoff, C.; Chang, Y.; Moore, P.; Weiss, R.A.; Mittnacht, S. The Cyclin Encoded by Kaposi’s Sarcoma-Associated Herpesvirus Stimulates Cdk6 to Phosphorylate the Retinoblastoma Protein and Histone H1. J. Virol. 1997, 71, 4193.
  237. Gupta, N.; Thakker, S.; Verma, S.C. KSHV Encoded LANA Recruits Nucleosome Assembly Protein NAP1L1 for Regulating Viral DNA Replication and Transcription. Sci. Rep. 2016, 6, 32633.
  238. Friborg, J.; Kong, W.; Hottiger, M.O.; Nabel, G.J. P53 Inhibition by the LANA Protein of KSHV Protects against Cell Death. Nature 1999, 402, 889–894.
  239. Bubman, D.; Guasparri, I.; Cesarman, E. Deregulation of C-Myc in Primary Effusion Lymphoma by Kaposi’s Sarcoma Herpesvirus Latency-Associated Nuclear Antigen. Oncogene 2007, 26, 4979–4986.
  240. Di Bartolo, D.L.; Cannon, M.; Liu, Y.-F.; Renne, R.; Chadburn, A.; Boshoff, C.; Cesarman, E. KSHV LANA Inhibits TGF-β Signaling through Epigenetic Silencing of the TGF-β Type II Receptor. Blood 2008, 111, 4731–4740.
  241. DiMaio, T.A.; Vogt, D.T.; Lagunoff, M. KSHV Requires VCyclin to Overcome Replicative Senescence in Primary Human Lymphatic Endothelial Cells. PLoS Pathog. 2020, 16, e1008634.
  242. Juillard, F.; Tan, M.; Li, S.; Kaye, K.M. Kaposi’s Sarcoma Herpesvirus Genome Persistence. Front. Microbiol. 2016, 7, 1149.
  243. Fujimuro, M.; Liu, J.; Zhu, J.; Yokosawa, H.; Hayward, S.D. Regulation of the Interaction between Glycogen Synthase Kinase 3 and the Kaposi’s Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen. J. Virol. 2005, 79, 10429.
  244. Fujimuro, M.; Wu, F.Y.; apRhys, C.; Kajumbula, H.; Young, D.B.; Hayward, G.S.; Hayward, S.D. A Novel Viral Mechanism for Dysregulation of β-Catenin in Kaposi’s Sarcoma–Associated Herpesvirus Latency. Nat. Med. 2003, 9, 300–306.
  245. Radkov, S.A.; Kellam, P.; Boshoff, C. The Latent Nuclear Antigen of Kaposi Sarcoma-Associated Herpesvirus Targets the Retinoblastoma–E2F Pathway and with the Oncogene Hras Transforms Primary Rat Cells. Nat. Med. 2000, 6, 1121–1127.
  246. Liu, J.; Martin, H.J.; Liao, G.; Hayward, S.D. The Kaposi’s Sarcoma-Associated Herpesvirus LANA Protein Stabilizes and Activates c-Myc. J. Virol. 2007, 81, 10451.
  247. Gordon, M.Y.; Marley, S.B.; Lewis, J.L.; Davidson, R.J.; Nguyen, D.X.; Grand, F.H.; Amos, T.A.; Goldman, J.M. Treatment with Interferon-Alpha Preferentially Reduces the Capacity for Amplification of Granulocyte-Macrophage Progenitors (CFU-GM) from Patients with Chronic Myeloid Leukemia but Spares Normal CFU-GM. J. Clin. Investig. 1998, 102, 710–715.
  248. Chen, W.; Hilton, I.B.; Staudt, M.R.; Burd, C.E.; Dittmer, D.P. Distinct P53, P53:LANA, and LANA Complexes in Kaposi’s Sarcoma-Associated Herpesvirus Lymphomas. J. Virol. 2010, 84, 3898.
  249. Shamay, M.; Krithivas, A.; Zhang, J.; Hayward, S.D. Recruitment of the de Novo DNA Methyltransferase Dnmt3a by Kaposi’s Sarcoma-Associated Herpesvirus LANA. Proc. Natl. Acad. Sci. USA 2006, 103, 14554.
  250. Hu, J.; Yang, Y.; Turner, P.C.; Jain, V.; McIntyre, L.M.; Renne, R. LANA Binds to Multiple Active Viral and Cellular Promoters and Associates with the H3K4methyltransferase HSET1 Complex. PLoS Pathog. 2014, 10, e1004240.
  251. Mercier, A.; Arias, C.; Madrid, A.S.; Holdorf, M.M.; Ganem, D. Site-Specific Association with Host and Viral Chromatin by Kaposi’s Sarcoma-Associated Herpesvirus LANA and Its Reversal during Lytic Reactivation. J. Virol. 2014, 88, 6762.
  252. Lu, F.; Tsai, K.; Chen, H.-S.; Wikramasinghe, P.; Davuluri, R.V.; Showe, L.; Domsic, J.; Marmorstein, R.; Lieberman, P.M. Identification of Host-Chromosome Binding Sites and Candidate Gene Targets for Kaposi’s Sarcoma-Associated Herpesvirus LANA. J. Virol. 2012, 86, 5752.
  253. Viejo-Borbolla, A.; Ottinger, M.; Brüning, E.; Bürger, A.; König, R.; Kati, E.; Sheldon, J.A.; Schulz, T.F. Brd2/RING3 Interacts with a Chromatin-Binding Domain in the Kaposi’s Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 (LANA-1) That Is Required for Multiple Functions of LANA-1. J. Virol. 2005, 79, 13618.
  254. Ottinger, M.; Christalla, T.; Nathan, K.; Brinkmann, M.M.; Viejo-Borbolla, A.; Schulz, T.F. Kaposi’s Sarcoma-Associated Herpesvirus LANA-1 Interacts with the Short Variant of BRD4 and Releases Cells from a BRD4- and BRD2/RING3-Induced G1 Cell CycleArrest. J. Virol. 2006, 80, 10772.
  255. Hellert, J.; Weidner-Glunde, M.; Krausze, J.; Richter, U.; Adler, H.; Fedorov, R.; Pietrek, M.; Rückert, J.; Ritter, C.; Schulz, T.F.; et al. A Structural Basis for BRD2/4-Mediated Host Chromatin Interaction and Oligomer Assembly of Kaposi Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus LANA Proteins. PLoS Pathog. 2013, 9, e1003640.
  256. Lotke, R.; Schneeweiß, U.; Pietrek, M.; Günther, T.; Grundhoff, A.; Weidner-Glunde, M.; Schulz, T.F. Brd/BET Proteins Influence the Genome-Wide Localization of the Kaposi’s Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus Major Latency Proteins. Front. Microbiol. 2020, 11, 591778.
  257. Lippert, T.P.; Marzec, P.; Idilli, A.I.; Sarek, G.; Vancevska, A.; Bower, M.; Farrell, P.J.; Ojala, P.M.; Feldhahn, N.; Boulton, S.J. Oncogenic Herpesvirus KSHV Triggers Hallmarks of Alternative Lengthening of Telomeres. Nat. Commun. 2021, 12, 512.
  258. He, M.; Zhang, W.; Bakken, T.; Schutten, M.; Toth, Z.; Jung, J.U.; Gill, P.; Cannon, M.; Gao, S.-J. Cancer Angiogenesis Induced by Kaposi Sarcoma-Associated Herpesvirus Is Mediated by EZH2. Cancer Res. 2012, 72, 3582–3592.
  259. Lang, F.; Sun, Z.; Pei, Y.; Singh, R.K.; Jha, H.C.; Robertson, E.S. Shugoshin 1 Is Dislocated by KSHV-Encoded LANA Inducing Aneuploidy. PLoS Pathog. 2018, 14, e1007253.
  260. Rossetto, C.C.; Tarrant-Elorza, M.; Verma, S.; Purushothaman, P.; Pari, G.S. Regulation of Viral and Cellular Gene Expression by Kaposi’s Sarcoma-Associated Herpesvirus Polyadenylated Nuclear RNA. J. Virol. 2013, 87, 5540.
  261. Rossetto, C.C.; Pari, G. KSHV PAN RNA Associates with Demethylases UTX and JMJD3 to Activate Lytic Replication through a Physical Interaction with the Virus Genome. PLoS Pathog. 2012, 8, e1002680.
  262. Rossetto, C.C.; Pari, G.S. Kaposi’s Sarcoma-Associated Herpesvirus Noncoding Polyadenylated Nuclear RNA Interacts with Virus- and Host Cell-Encoded Proteins and Suppresses Expression of Genes Involved in Immune Modulation. J. Virol. 2011, 85, 13290.
  263. Wu, J.; Xu, Y.; Mo, D.; Huang, P.; Sun, R.; Huang, L.; Pan, S.; Xu, J. Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) VIL-6 Promotes Cell Proliferation and Migration by Upregulating DNMT1 via STAT3 Activation. PLoS ONE 2014, 9, e93478.
  264. Li, W.; Wang, Q.; Feng, Q.; Wang, F.; Yan, Q.; Gao, S.-J.; Lu, C. Oncogenic KSHV-Encoded Interferon Regulatory Factor Upregulates HMGB2 and CMPK1 Expression to Promote Cell Invasion by Disrupting a Complex LncRNA-OIP5-AS1/MiR-218-5p Network. PLoS Pathog. 2019, 15, e1007578.
  265. Lin, R.; Genin, P.; Mamane, Y.; Sgarbanti, M.; Battistini, A.; Harrington, W.J.; Barber, G.N.; Hiscott, J. HHV-8 Encoded VIRF-1 Represses the Interferon Antiviral Response by Blocking IRF-3 Recruitment of the CBP/P300 Coactivators. Oncogene 2001, 20, 800–811.
  266. Seo, T.; Park, J.; Choe, J. Kaposi’s Sarcoma–Associated Herpesvirus Viral IFN Regulatory Factor 1 Inhibits Transforming Growth Factor-β Signaling. Cancer Res. 2005, 65, 1738–1747.
  267. Kirchhoff, S.; Sebens, T.; Baumann, S.; Krueger, A.; Zawatzky, R.; Li-Weber, M.; Meinl, E.; Neipel, F.; Fleckenstein, B.; Krammer, P.H. Viral IFN-Regulatory Factors Inhibit Activation-Induced Cell Death Via Two Positive Regulatory IFN-Regulatory Factor 1-Dependent Domains in the CD95 Ligand Promoter. J. Immunol. 2002, 168, 1226.
  268. Lee, H.-R.; Li, F.; Choi, U.Y.; Yu, H.R.; Aldrovandi, G.M.; Feng, P.; Gao, S.-J.; Hong, Y.-K.; Jung, J.U. Deregulation of HDAC5 by Viral Interferon Regulatory Factor 3 Plays an Essential Role in Kaposi’s Sarcoma-Associated Herpesvirus-Induced Lymphangiogenesis. mBio 2018, 9, e02217-17.
  269. Manzano, M.; Günther, T.; Ju, H.; Nicholas, J.; Bartom, E.T.; Grundhoff, A.; Gottwein, E. Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma. mBio 2020, 11, e01457-20.
  270. Park, A.; Oh, S.; Jung, K.L.; Choi, U.Y.; Lee, H.-R.; Rosenfeld, M.G.; Jung, J.U. Global Epigenomic Analysis of KSHV-Infected Primary Effusion Lymphoma Identifies Functional MYC Superenhancers and Enhancer RNAs. Proc. Natl. Acad. Sci. USA 2020, 117, 21618–21627.
  271. Liu, D.; Wang, Y.; Yuan, Y. Kaposi’s Sarcoma-Associated Herpesvirus K8 Is an RNA Binding Protein That Regulates Viral DNA Replication in Coordination with a Noncoding RNA. J. Virol. 2018, 92, e02177-17.
  272. Francies, F.Z.; Dlamini, Z. Aberrant Splicing Events and Epigenetics in Viral Oncogenomics: Current Therapeutic Strategies. Cells 2021, 10, 239.
  273. Naipauer, J.; Rosario, S.; Gupta, S.; Premer, C.; Méndez-Solís, O.; Schlesinger, M.; Ponzinibbio, V.; Jain, V.; Gay, L.; Renne, R.; et al. PDGFRA Defines the Mesenchymal Stem Cell Kaposi’s Sarcoma Progenitors by Enabling KSHV Oncogenesis in an Angiogenic Environment. PLoS Pathog. 2019, 15, e1008221.
  274. McHugh, D.; Caduff, N.; Barros, M.H.M.; Rämer, P.C.; Raykova, A.; Murer, A.; Landtwing, V.; Quast, I.; Styles, C.T.; Spohn, M.; et al. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host Microbe 2017, 22, 61–73.e7.
  275. Wang, C.; Zhang, L.; Ke, L.; Ding, W.; Jiang, S.; Li, D.; Narita, Y.; Hou, I.; Liang, J.; Li, S.; et al. Primary Effusion Lymphoma Enhancer Connectome Links Super-Enhancers to Dependency Factors. Nat. Commun. 2020, 11, 6318.
  276. Van Damme, E.; Van Loock, M. Functional Annotation of Human Cytomegalovirus Gene Products: An Update. Front. Microbiol. 2014, 5, 218.
  277. Saccoccio, F.M.; Gallagher, M.K.; Adler, S.P.; McVoy, M.A. Neutralizing Activity of Saliva against Cytomegalovirus. Clin. Vaccine Immunol. 2011, 18, 1536–1542.
  278. Ryckman, B.J.; Rainish, B.L.; Chase, M.C.; Borton, J.A.; Nelson, J.A.; Jarvis, M.A.; Johnson, D.C. Characterization of the Human Cytomegalovirus GH/GL/UL128-131 Complex that Mediates Entry into Epithelial and Endothelial Cells. J. Virol. 2008, 82, 60.
  279. Sinzger, C.; Digel, M.; Jahn, G. Cytomegalovirus Cell Tropism. Curr. Top. Microbiol. Immunol. 2008, 325, 63–83.
  280. Preece, P.M.; Blount, J.M.; Glover, J.; Fletcher, G.M.; Peckham, C.S.; Griffiths, P.D. The Consequences of Primary Cytomegalovirus Infection in Pregnancy. Arch. Dis. Child. 1983, 58, 970.
  281. Fortunato, E.A.; Dell’Aquila, M.L.; Spector, D.H. Specific Chromosome 1 Breaks Induced by Human Cytomegalovirus. Proc. Natl. Acad. Sci. USA 2000, 97, 853.
  282. Nystad, M.; Fagerheim, T.; Brox, V.; Fortunato, E.A.; Nilssen, Ø. Human Cytomegalovirus (HCMV) and Hearing Impairment: Infection of Fibroblast Cells with HCMV Induces Chromosome Breaks at 1q23.3, between Loci DFNA7 and DFNA49—Both Involved in Dominantly Inherited, Sensorineural, Hearing Impairment. Mutat. Res. Mol. Mech. Mutagen. 2008, 637, 56–65.
  283. Kuan, M.I.; Jaeger, H.K.; Balemba, O.B.; O’Dowd, J.M.; Duricka, D.; Hannemann, H.; Marx, E.; Teissier, N.; Gabrielli, L.; Bonasoni, M.P.; et al. Human Cytomegalovirus Interactions with the Basement Membrane Protein Nidogen 1. J. Virol. 2021, 95, e01506-20.
  284. Kumar, A.; Tripathy, M.K.; Pasquereau, S.; Al Moussawi, F.; Abbas, W.; Coquard, L.; Khan, K.A.; Russo, L.; Algros, M.-P.; Valmary-Degano, S.; et al. The Human Cytomegalovirus Strain DB Activates Oncogenic Pathways in Mammary Epithelial Cells. EBioMedicine 2018, 30, 167–183.
  285. Baryawno, N.; Rahbar, A.; Wolmer-Solberg, N.; Taher, C.; Odeberg, J.; Darabi, A.; Khan, Z.; Sveinbjörnsson, B.; FuskevÅg, O.-M.; Segerström, L.; et al. Detection of Human Cytomegalovirus in Medulloblastomas Reveals a Potential Therapeutic Target. J. Clin. Investig. 2011, 121, 4043–4055.
  286. Wolmer-Solberg, N.; Baryawno, N.; Rahbar, A.; Fuchs, D.; Odeberg, J.; Taher, C.; Wilhelmi, V.; Milosevic, J.; Mohammad, A.-A.; Martinsson, T.; et al. Frequent Detection of Human Cytomegalovirus in Neuroblastoma: A Novel Therapeutic Target? Int. J. Cancer 2013, 133, 2351–2361.
  287. Price, R.L.; Bingmer, K.; Harkins, L.; Iwenofu, O.H.; Kwon, C.-H.; Cook, C.; Pelloski, C.; Chiocca, E.A. Cytomegalovirus Infection Leads to Pleomorphic Rhabdomyosarcomas in Trp53+/− Mice. Cancer Res. 2012, 72, 5669–5674.
  288. Cobbs, C.S.; Harkins, L.; Samanta, M.; Gillespie, G.Y.; Bharara, S.; King, P.H.; Nabors, L.B.; Cobbs, C.G.; Britt, W.J. Human Cytomegalovirus Infection and Expression in Human Malignant Glioma. Cancer Res. 2002, 62, 3347.
  289. Rahbar, A.; Orrego, A.; Peredo, I.; Dzabic, M.; Wolmer-Solberg, N.; Strååt, K.; Stragliotto, G.; Söderberg-Nauclér, C. Human Cytomegalovirus Infection Levels in Glioblastoma Multiforme Are of Prognostic Value for Survival. J. Clin. Virol. 2013, 57, 36–42.
  290. Krenzlin, H.; Behera, P.; Lorenz, V.; Passaro, C.; Zdioruk, M.; Nowicki, M.O.; Grauwet, K.; Zhang, H.; Skubal, M.; Ito, H.; et al. Cytomegalovirus Promotes Murine Glioblastoma Growth via Pericyte Recruitment and Angiogenesis. J. Clin. Investig. 2019, 129, 1671–1683.
  291. Stragliotto, G.; Rahbar, A.; Solberg, N.W.; Lilja, A.; Taher, C.; Orrego, A.; Bjurman, B.; Tammik, C.; Skarman, P.; Peredo, I.; et al. Effects of Valganciclovir as an Add-on Therapy in Patients with Cytomegalovirus-Positive Glioblastoma: A Randomized, Double-Blind, Hypothesis-Generating Study. Int. J. Cancer 2013, 133, 1204–1213.
  292. Stragliotto, G.; Pantalone, M.R.; Rahbar, A.; Bartek, J.; Söderberg-Naucler, C. Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients. Clin. Cancer Res. 2020, 26, 4031.
  293. Stragliotto, G.; Pantalone, M.R.; Rahbar, A.; Söderberg-Nauclér, C. Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma. Microorganisms 2020, 8, 1471.
  294. Cobbs, C.; Khan, S.; Matlaf, L.; McAllister, S.; Zider, A.; Yount, G.; Rahlin, K.; Harkins, L.; Bezrookove, V.; Singer, E.; et al. HCMV Glycoprotein B Is Expressed in Primary Glioblastomas and Enhances Growth and Invasiveness via PDGFR-Alpha Activation. Oncotarget 2014, 5, 1091.
  295. Cojohari, O.; Peppenelli, M.A.; Chan, G.C. Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes. J. Virol. 2016, 90, 6443.
  296. Mahmud, J.; Miller, M.J.; Altman, A.M.; Chan, G.C. Human Cytomegalovirus Glycoprotein-Initiated Signaling Mediates the Aberrant Activation of Akt. J. Virol. 2020, 94.
  297. Costa, H.; Nascimento, R.; Sinclair, J.; Parkhouse, R.M.E. Human Cytomegalovirus Gene UL76 Induces IL-8 Expression through Activation of the DNA Damage Response. PLoS Pathog. 2013, 9, e1003609.
  298. Herbein, G. The Human Cytomegalovirus, from Oncomodulation to Oncogenesis. Viruses 2018, 10, 408.
  299. Moussawi, F.A.; Kumar, A.; Pasquereau, S.; Tripathy, M.K.; Karam, W.; Diab-Assaf, M.; Herbein, G. The Transcriptome of Human Mammary Epithelial Cells Infected with the HCMV-DB Strain Displays Oncogenic Traits. Sci. Rep. 2018, 8, 12574.
  300. Nehme, Z.; Pasquereau, S.; Haidar Ahmad, S.; Coaquette, A.; Molimard, C.; Monnien, F.; Algros, M.-P.; Adotevi, O.; Diab Assaf, M.; Feugeas, J.-P.; et al. Polyploid Giant Cancer Cells, Stemness and Epithelial-Mesenchymal Plasticity Elicited by Human Cytomegalovirus. Oncogene 2021, 40, 3030–3046.
  301. Harkins, L.E.; Matlaf, L.A.; Soroceanu, L.; Klemm, K.; Britt, W.J.; Wang, W.; Bland, K.I.; Cobbs, C.S. Detection of Human Cytomegalovirus in Normal and Neoplastic Breast Epithelium. Herpesviridae 2010, 1, 8.
  302. Soroceanu, L.; Matlaf, L.; Khan, S.; Akhavan, A.; Singer, E.; Bezrookove, V.; Decker, S.; Ghanny, S.; Hadaczek, P.; Bengtsson, H.; et al. Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma. Cancer Res. 2015, 75, 3065–3076.
  303. Taher, C.; de Boniface, J.; Mohammad, A.-A.; Religa, P.; Hartman, J.; Yaiw, K.-C.; Frisell, J.; Rahbar, A.; Söderberg-Naucler, C. High Prevalence of Human Cytomegalovirus Proteins and Nucleic Acids in Primary Breast Cancer and Metastatic Sentinel Lymph Nodes. PLoS ONE 2013, 8, e56795.
  304. Jones, B.C.; Logsdon, N.J.; Josephson, K.; Cook, J.; Barry, P.A.; Walter, M.R. Crystal Structure of Human Cytomegalovirus IL-10 Bound to Soluble Human IL-10R1. Proc. Natl. Acad. Sci. USA 2002, 99, 9404.
  305. Gruber, S.G.; Gloria Luciani, M.; Grundtner, P.; Zdanov, A.; Gasche, C. Differential Signaling of CmvIL-10 through Common Variants of the IL-10 Receptor 1. Eur. J. Immunol. 2008, 38, 3365–3375.
  306. Raftery, M.J.; Wieland, D.; Gronewald, S.; Kraus, A.A.; Giese, T.; Schönrich, G. Shaping Phenotype, Function, and Survival of Dendritic Cells by Cytomegalovirus-Encoded IL-10. J. Immunol. 2004, 173, 3383.
  307. Banerjee, N.S.; Moore, D.W.; Broker, T.R.; Chow, L.T. Vorinostat, a Pan-HDAC Inhibitor, Abrogates Productive HPV-18 DNA Amplification. Proc. Natl. Acad. Sci. USA 2018, 115, E11138.
  308. Dziurzynski, K.; Wei, J.; Qiao, W.; Hatiboglu, M.A.; Kong, L.-Y.; Wu, A.; Wang, Y.; Cahill, D.; Levine, N.B.; Prabhu, S.; et al. Glioma-Associated Cytomegalovirus Mediates Subversion of the Monocyte Lineage to a Tumor Propagating Phenotype. Clin. Cancer Res. 2011, 17, 4642–4649.
  309. Zhang, X.; Liu, P.; Zhang, B.; Wang, A.; Yang, M. Role of STAT3 Decoy Oligodeoxynucleotides on Cell Invasion and Chemosensitivity in Human Epithelial Ovarian Cancer Cells. Cancer Genet. Cytogenet. 2010, 197, 46–53.
  310. Bishop, R.K.; Valle Oseguera, C.A.; Spencer, J.V. Human Cytomegalovirus Interleukin-10 Promotes Proliferation and Migration of MCF-7 Breast Cancer Cells. Cancer Cell Microenviron. 2015, 2, e678.
  311. Rölle, A.; Mousavi-Jazi, M.; Eriksson, M.; Odeberg, J.; Söderberg-Nauclér, C.; Cosman, D.; Kärre, K.; Cerboni, C. Effects of Human Cytomegalovirus Infection on Ligands for the Activating NKG2D Receptor of NK Cells: Up-Regulation of UL16-Binding Protein (ULBP)1 and ULBP2 Is Counteracted by the Viral UL16 Protein. J. Immunol. 2003, 171, 902.
  312. Goldmacher, V.S. Cell Death Suppression by Cytomegaloviruses. Apoptosis 2005, 10, 251–265.
  313. Lin, S.-R.; Jiang, M.J.; Wang, H.-H.; Hu, C.-H.; Hsu, M.-S.; Hsi, E.; Duh, C.-Y.; Wang, S.-K. Human Cytomegalovirus UL76 Elicits Novel Aggresome Formation via Interaction with S5a of the Ubiquitin Proteasome System. J. Virol. 2013, 87, 11562–11578.
  314. Zhang, W.; Yao, Y.; Chen, J.; Wang, M. Unconserved C Terminal of Human Cytomegalovirus Tegument Protein PUL76 Elicits Nuclear Aggresome Formation and Induces DNA Damage in Transfected Cells. J. Biomed. Sci. 2015, 22, 95.
  315. Winkler, L.L.; Hwang, J.; Kalejta, R.F. Ubiquitin-Independent Proteasomal Degradation of Tumor Suppressors by Human Cytomegalovirus Pp71 Requires the 19S Regulatory Particle. J. Virol. 2013, 87, 4665.
  316. Kalejta, R.F.; Bechtel, J.T.; Shenk, T. Human Cytomegalovirus Pp71 Stimulates Cell Cycle Progression by Inducing the Proteasome-Dependent Degradation of the Retinoblastoma Family of Tumor Suppressors. Mol. Cell. Biol. 2003, 23, 1885–1895.
  317. Arnon, T.I.; Achdout, H.; Levi, O.; Markel, G.; Saleh, N.; Katz, G.; Gazit, R.; Gonen-Gross, T.; Hanna, J.; Nahari, E.; et al. Inhibition of the NKp30 Activating Receptor by Pp65 of Human Cytomegalovirus. Nat. Immunol. 2005, 6, 515–523.
  318. Li, T.; Chen, J.; Cristea, I.M. Human Cytomegalovirus Tegument Protein PUL83 Inhibits IFI16-Mediated DNA Sensing for Immune Evasion. Cell Host Microbe 2013, 14, 591–599.
  319. Iwahori, S.; Umaña, A.C.; VanDeusen, H.R.; Kalejta, R.F. Human Cytomegalovirus-Encoded Viral Cyclin-Dependent Kinase (v-CDK) UL97 Phosphorylates and Inactivates the Retinoblastoma Protein-Related P107 and P130 Proteins. J. Biol. Chem. 2017, 292, 6583–6599.
  320. Biolatti, M.; Dell’Oste, V.; Pautasso, S.; von Einem, J.; Marschall, M.; Plachter, B.; Gariglio, M.; De Andrea, M.; Landolfo, S. Regulatory Interaction between the Cellular Restriction Factor IFI16 and Viral Pp65 (PUL83) Modulates Viral Gene Expression and IFI16 Protein Stability. J. Virol. 2016, 90, 8238–8250.
  321. Steingruber, M.; Marschall, M. The Cytomegalovirus Protein Kinase PUL97: Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting. Microorganisms 2020, 8, 515.
  322. Ren, Y.; Yang, J.; Li, M.; Huang, N.; Chen, Y.; Wu, X.; Wang, X.; Qiu, S.; Wang, H.; Li, X. Viral IL-10 Promotes Cell Proliferation and Cell Cycle Progression via JAK2/STAT3 Signaling Pathway in Nasopharyngeal Carcinoma Cells. Biotechnol. Appl. Biochem. 2020, 67, 929–938.
  323. Banerjee, K.; Resat, H. Constitutive Activation of STAT3 in Breast Cancer Cells: A Review. Int. J. Cancer 2016, 138, 2570–2578.
  324. Valle Oseguera, C.A.; Spencer, J.V. Human Cytomegalovirus Interleukin-10 Enhances Matrigel Invasion of MDA-MB-231 Breast Cancer Cells. Cancer Cell Int. 2017, 17, 24.
  325. Yu, Y.; Alwine, J.C. Human Cytomegalovirus Major Immediate-Early Proteins and Simian Virus 40 Large T Antigen Can Inhibit Apoptosis through Activation of the Phosphatidylinositide 3′-OH Kinase Pathway and the Cellular Kinase Akt. J. Virol. 2002, 76, 3731.
  326. Hwang, E.-S.; Zhang, Z.; Cai, H.; Huang, D.Y.; Huong, S.-M.; Cha, C.-Y.; Huang, E.-S. Human Cytomegalovirus IE1-72 Protein Interacts with P53 and Inhibits P53-Dependent Transactivation by a Mechanism Different from That of IE2-86 Protein. J. Virol. 2009, 83, 12388.
  327. Yoo, Y.D.; Chiou, C.J.; Choi, K.S.; Yi, Y.; Michelson, S.; Kim, S.; Hayward, G.S.; Kim, S.J. The IE2 Regulatory Protein of Human Cytomegalovirus Induces Expression of the Human Transforming Growth Factor Beta1 Gene through an Egr-1 Binding Site. J. Virol. 1996, 70, 7062–7070.
  328. Lepiller, Q.; Aziz Khan, K.; Di Martino, V.; Herbein, G. Cytomegalovirus and Tumors: Two Players for One Goal-Immune Escape. Open Virol. J. 2011, 5, 60–69.
  329. Kulkarni, A.S.; Fortunato, E.A. Modulation of Homology-Directed Repair in T98G Glioblastoma Cells Due to Interactions between Wildtype P53, Rad51 and HCMV IE1-72. Viruses 2014, 6, 968.
  330. Ran, X.; Bian, X.; Ji, Y.; Yan, X.; Yang, F.; Li, F. White Spot Syndrome Virus IE1 and WSV056 Modulate the G1/S Transition by Binding to the Host Retinoblastoma Protein. J. Virol. 2013, 87, 12576–12582.
  331. Cinatl, J., Jr.; Nevels, M.; Paulus, C.; Michaelis, M. Activation of Telomerase in Glioma Cells by Human Cytomegalovirus: Another Piece of the Puzzle. JNCI J. Natl. Cancer Inst. 2009, 101, 441–443.
  332. de Wit, R.H.; Mujić-Delić, A.; van Senten, J.R.; Fraile-Ramos, A.; Siderius, M.; Smit, M.J. Human Cytomegalovirus Encoded Chemokine Receptor US28 Activates the HIF-1α/PKM2 Axis in Glioblastoma Cells. Oncotarget 2016, 7, 67966.
  333. Krishna, B.A.; Miller, W.E.; O’Connor, C.M. US28: HCMV’s Swiss Army Knife. Viruses 2018, 10, 445.
  334. Fielding, C.A.; Aicheler, R.; Stanton, R.J.; Wang, E.C.Y.; Han, S.; Seirafian, S.; Davies, J.; McSharry, B.P.; Weekes, M.P.; Antrobus, P.R.; et al. Two Novel Human Cytomegalovirus NK Cell Evasion Functions Target MICA for Lysosomal Degradation. PLoS Pathog. 2014, 10, e1004058.
  335. Rossetto, C.C.; Tarrant-Elorza, M.; Pari, G.S. Cis and Trans Acting Factors Involved in Human Cytomegalovirus Experimental and Natural Latent Infection of CD14 (+) Monocytes and CD34 (+) Cells. PLoS Pathog. 2013, 9, e1003366.
  336. Reeves, M.B.; Davies, A.A.; McSharry, B.P.; Wilkinson, G.W.; Sinclair, J.H. Complex I Binding by a Virally Encoded RNA Regulates Mitochondria-Induced Cell Death. Science 2007, 316, 1345.
  337. Ahmed, W.; Liu, Z.-F. Long Non-Coding RNAs: Novel Players in Regulation of Immune Response upon Herpesvirus Infection. Front. Immunol. 2018, 9, 761.
  338. Oberstein, A.; Shenk, T. Cellular Responses to Human Cytomegalovirus Infection: Induction of a Mesenchymal-to-Epithelial Transition (MET) Phenotype. Proc. Natl. Acad. Sci. USA 2017, 114, E8244.
  339. Koldehoff, M.; Lindemann, M.; Opalka, B.; Bauer, S.; Ross, R.S.; Elmaagacli, A.H. Cytomegalovirus Induces Apoptosis in Acute Leukemia Cells as a Virus-versus-Leukemia Function. Leuk. Lymphoma 2015, 56, 3189–3197.
  340. Elmaagacli, A.H.; Steckel, N.K.; Koldehoff, M.; Hegerfeldt, Y.; Trenschel, R.; Ditschkowski, M.; Christoph, S.; Gromke, T.; Kordelas, L.; Ottinger, H.D.; et al. Early Human Cytomegalovirus Replication after Transplantation Is Associated with a Decreased Relapse Risk: Evidence for a Putative Virus-versus-Leukemia Effect in Acute Myeloid Leukemia Patients. Blood 2011, 118, 1402–1412.
  341. Green, M.L.; Leisenring, W.M.; Xie, H.; Walter, R.B.; Mielcarek, M.; Sandmaier, B.M.; Riddell, S.R.; Boeckh, M. CMV Reactivation after Allogeneic HCT and Relapse Risk: Evidence for Early Protection in Acute Myeloid Leukemia. Blood 2013, 122, 1316–1324.
  342. Koldehoff, M.; Ross, S.R.; Dührsen, U.; Beelen, D.W.; Elmaagacli, A.H. Early CMV-Replication after Allogeneic Stem Cell Transplantation Is Associated with a Reduced Relapse Risk in Lymphoma. Leuk. Lymphoma 2017, 58, 822–833.
  343. Kumar, A.; Coquard, L.; Pasquereau, S.; Russo, L.; Valmary-Degano, S.; Borg, C.; Pothier, P.; Herbein, G. Tumor Control by Human Cytomegalovirus in a Murine Model of Hepatocellular Carcinoma. Mol. Ther. Oncolytics 2016, 3, 16012.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback